SGP — SpyGlass Pharma, Inc. Common Stock stock price, charts and financials

QT52SpyGlass Pharma, Inc. Common Stock

SpyGlass Pharma, Inc. Common Stock (NASDAQ: SGP) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
22.68
+0.15+0.67%
OverviewShort InterestFilings
SGPQT52SpyGlass Pharma, Inc. Common Stock·NASDAQ
22.68+0.67%
TA
Loading chart...
Screen all →
IOVA+6.14%$4.32FTRE-1.20%$18.94SLS+12.09%$11.22URGN+0.92%$38.59MESO+2.12%$14.47TSHA-1.37%$5.78TYRA+0.50%$32.04AUPH-2.08%$14.57
Snapshot
Index-P/E-EPS (ttm)-Insider Own-Shs Outstand33.43MPerf Week9.96%
Market Cap753.25MForward P/E-EPS next Y-2.69Insider Trans-Shs Float13.95MPerf Month15.72%
Enterprise Value515.96MPEG-EPS next Q-0.52Inst Own127.23%Short Float3.38%Perf Quarter-1.79%
Income-44.22MP/S0.00EPS this Y-Inst Trans-Short Ratio11.02Perf Half Y-
Sales0.00P/B1.80EPS next Y-18.13%ROA-10.21%Short Interest1.13MPerf YTD-6.12%
Book/sh-P/C-EPS next 5Y-ROE-123.53%52W High32.66 -30.55%Perf Year-
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-11.54%52W Low17.17 32.06%Perf 3Y-
Dividend Est.-EV/EBITDA-Sales past 3/5Y-Gross Margin0.00%Volatility5.74% 7.71%Perf 5Y-
Dividend TTM-EV/Sales0.00EPS Y/Y TTM-Oper. Margin0.00%ATR (14)1.51Perf 10Y-
Dividend Ex-Date-Quick Ratio38.00Sales Y/Y TTM-Profit Margin0.00%RSI (14)61.01Recom-
Dividend Gr. 3/5Y-Current Ratio38.00EPS Q/Q-SMA208.71%Beta1.40Target Price62.00
Payout0.00%Debt/Eq0.01Sales Q/Q-SMA5012.81%Rel Volume0.56Prev Close22.53
Employees65LT Debt/Eq-0.02EarningsAug 13SMA200-2.41%Avg Volume111.11KPrice22.68
IPO DateFeb 06, 2026Option/ShortNo / YesEPS/Sales Surpr.-896.13% -Net Debt/EBITDA9.18Volume61,842Change0.67%
Analyst Ratings
DateActionAnalystRatingTarget
Mar-03-26ReiteratedJefferies$62
Latest News
Company

SpyGlass Pharma, Inc. is an advanced biopharmaceutical company dedicated to developing innovative therapeutic approaches for individuals suffering from chronic eye conditions. Its flagship investigational product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), is engineered for implantation during standard cataract removal procedures with the aim of reducing elevated intraocular pressure (IOP) in patients afflicted with either open-angle glaucoma (OAG) or ocular hypertension (OHT). Co-founded in January 2019 by Malik Y. Kahook and Glenn Sussman, the company maintains its headquarters in Aliso Viejo, CA.

Ownership
Total institutional ownership127.23%

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
Total Revenue
0
Cost of Goods Sold Incl. D&A1
Gross Profit-1
Selling, General and Administrative Excl. Other12
Research and Development29
Other Operating Expense
0
Operating Income-41
Interest Expense
0
Unusual Expense
—
Non-Operating Income (Expense)2
Net Income Before Taxes-40
Income Taxes
0
Consolidated Net Income-40
Net Income From Continuing Operations-40
Net Income-40
EPS (Recurring)-1.19
EPS (Basic, Before Extraordinaries)-1.19
EPS (Diluted)-1.19
EBITDA-39
Other After Tax Adjustments
—
Stock Option Compensation Expense
—
Price To Earnings Ratio
—
Price To Sales Ratio
—
Gross Margin
—
Operating Margin
—
Net Margin
—
Shares Outstanding33
Market Capitalization
—
Operating Lease Expense
—
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.